A number of targeted anticancer compounds are now in clinical testing through our own product programs and those of our partners. Information on the relevant subtypes of each cancer can be found in the discussion of each compound.
12 compounds in clinical testingLast updated on April 24, 2015
Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.
* Therapeutic antibody
mBC: metastatic breast cancer BC: breast cancer NSCLC: non-small cell lung cancer DLBCL: diffuse large B-cell lymphoma
Based on information on clinicaltrials.gov or other public disclosures.
Last updated: April 24, 2015